Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Weyerhaeuser Company Common Stock (WY) vs Zoetis Inc (ZTS) Price & Performance

Weyerhaeuser Company Common StockTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Weyerhaeuser Company Common Stock vs Zoetis Inc — how do they compare? Weyerhaeuser Company Common Stock trades at $19.18 (market cap $13.62B), while Zoetis Inc trades at $75.93 (market cap $31.11B). The key difference: Zoetis Inc is far larger — about 2.3× Weyerhaeuser Company Common Stock's market cap, and Weyerhaeuser Company Common Stock pays the higher dividend (4.44%). Which is the better fit depends on your goals.

WYZTS
Market Cap
$13.62B$31.11B
Volume
8,637,0432,515,954
Sector
Real EstateHealth
52-Week High
$27.10$147.53
52-Week Low
$18.47$69.09
Enterprise Value
$18.54B$38.68B
Dividend Yield
4.44%2.82%
Typical Hold Time
—71 Days

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Weyerhaeuser Company Common Stock

Weyerhaeuser (WY) trades at $18.97, up 0.16% with neutral technical signals. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while fundamentals reveal modest profitability with 6.89% net margin and 4.97% ROE. Recent news highlights institutional accumulation and upcoming Q3 earnings on October 29. The company maintains stable revenue at $6.9B but faces cash flow challenges with negative net cash flow of $203M in 2025.

Weyerhaeuser presents a mixed outlook with analyst consensus favoring bullish sentiment (52% buy ratings) and a $29.33 price target suggesting 55% upside. However, risks include weak dividend coverage, high leverage at 5x, and sensitivity to interest rates and housing market cycles. The stock's current proximity to 52-week lows offers potential value but requires careful monitoring of lumber demand recovery and Q3 earnings results.

Zoetis Inc

Zoetis (ZTS) trades at $74.30, down 1.78% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 27.69% net income margin and 64.91% ROE, though recent Q1 2026 earnings missed expectations. Revenue growth has been steady, reaching $9.47B in 2025, while analyst consensus price target sits at $87.33 with 46.88% buy ratings. Recent news highlights competitive pressures in the U.S. companion animal market but acknowledges the company's industry-leading margins.

ZTS presents a compelling value opportunity with a P/E of 12.12 below sector averages, supported by robust cash flow generation and dividend payments. Near-term risks include U.S. market weakness and competitive pressures, but long-term growth drivers in international and livestock segments provide upside potential. The stock's current valuation reflects these headwinds, creating potential for appreciation as business conditions stabilize.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

WY

No sentiment data available yet.

ZTS
0% Buy100% Sell
Avg holding period · 71 Days

About Weyerhaeuser Company Common Stock

Weyerhaeuser Company is a timberland-focused real estate investment trust (REIT) that owns and manages more than 10 million acres of timberland in US, in addition to timberlands under long-term license in Canada. The company also manufactures wood products, including lumber, oriented strand board, and engineered wood.

Read more on WY →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →